선택지 정리됨

Mesothelioma: 국가별 선택지

이 페이지는 한국어 임상 치료 설명을 새로 쓰지 않습니다. 권위 출처, 진료 전 정리 질문, 임상시험 검색어, 구축 상태를 보여주는 안전한 시작점입니다.

선택지 정리됨고형암최종 확인 2026.06

현재 제공

국가별 선택지를 정리합니다

국가별로 출처가 연결된 선택지와 함께, 진단명·단계·검사 결과·진료과·임상시험 검색어를 정리합니다.

아직 하지 않음

치료 선택을 지시하지 않습니다

이 페이지는 치료 순위, 권장, 적합성 판단을 하지 않습니다.

출처

공신력 있는 출처 기반

모든 선택지는 규제·평가·지침 등 공신력 있는 출처에 연결되며, 새 출처가 검증되면 계속 확장됩니다.

진료 전 정리할 정보

이 항목은 원문 출처와 함께 의료진에게 확인하세요.
이 항목은 원문 출처와 함께 의료진에게 확인하세요.
이 항목은 원문 출처와 함께 의료진에게 확인하세요.
이 항목은 원문 출처와 함께 의료진에게 확인하세요.

임상시험 검색어

Mesothelioma clinical trial

국가별 선택지

국가별 치료 선택지

공식 규제·평가 기관 출처를 바탕으로 한 국가별 승인·접근 상태입니다. 무엇이 어디에 존재하는지를 보여줄 뿐, 추천이 아닙니다.

United States

Pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy [1]FDA-approvedNo biomarker requirement stated in fetched FDA approval notice; First-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma; KEYNOTE-483 enrolled patients with no prior systemic therapy for advanced/metastatic disease. · FDA approval notice does not establish payer coverage, individual eligibility, or choice versus other first-line options. Confidence/conflicts: High for U.S. approval; no superiority claim over other first-line regimens.
Pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy [1]FDA-approvedNo biomarker requirement stated in fetched FDA approval notice; First-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma; KEYNOTE-483 enrolled patients with no prior systemic therapy for advanced/metastatic disease. · FDA approval notice does not establish payer coverage, individual eligibility, or choice versus other first-line options. Confidence/conflicts: High for U.S. approval; no superiority claim over other first-line regimens.
Pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy [1]FDA-approvedNo biomarker requirement stated in fetched FDA approval notice; First-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma; KEYNOTE-483 enrolled patients with no prior systemic therapy for advanced/metastatic disease. · FDA approval notice does not establish payer coverage, individual eligibility, or choice versus other first-line options. Confidence/conflicts: High for U.S. approval; no superiority claim over other first-line regimens.

European Union

Ipilimumab (Yervoy) with nivolumab (Opdivo); pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy [2]EMA authorisedNo biomarker requirement stated in fetched EMA product pages for the MPM indications; First-line adult unresectable MPM; Keytruda indication specifically non-epithelioid MPM per fetched EMA source. · EMA central authorization does not establish Germany/France reimbursement timing or local prescribing restrictions. Histology matters for the fetched Keytruda EU indication. Confidence/conflicts: High for EU indication text; member-state access remains to verify.
Ipilimumab (Yervoy) with nivolumab (Opdivo); pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy [2]EMA authorisedNo biomarker requirement stated in fetched EMA product pages for the MPM indications; First-line adult unresectable MPM; Keytruda indication specifically non-epithelioid MPM per fetched EMA source. · EMA central authorization does not establish Germany/France reimbursement timing or local prescribing restrictions. Histology matters for the fetched Keytruda EU indication. Confidence/conflicts: High for EU indication text; member-state access remains to verify.
Ipilimumab (Yervoy) with nivolumab (Opdivo); pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy [2]EMA authorisedNo biomarker requirement stated in fetched EMA product pages for the MPM indications; First-line adult unresectable MPM; Keytruda indication specifically non-epithelioid MPM per fetched EMA source. · EMA central authorization does not establish Germany/France reimbursement timing or local prescribing restrictions. Histology matters for the fetched Keytruda EU indication. Confidence/conflicts: High for EU indication text; member-state access remains to verify.

United Kingdom

Nivolumab (Opdivo) with ipilimumab (Yervoy)[3]ApprovedNo biomarker requirement stated in fetched NICE TA818 recommendation; Untreated unresectable malignant pleural mesothelioma in adults. · NICE recommendation is conditional on ECOG performance status and commercial arrangement. Devolved nation implementation and local pathway details may vary. Confidence/conflicts: High for NICE recommendation in specified population; local implementation still needs care-team confirmation.
Nivolumab (Opdivo) with ipilimumab (Yervoy)[3]ApprovedNo biomarker requirement stated in fetched NICE TA818 recommendation; Untreated unresectable malignant pleural mesothelioma in adults. · NICE recommendation is conditional on ECOG performance status and commercial arrangement. Devolved nation implementation and local pathway details may vary. Confidence/conflicts: High for NICE recommendation in specified population; local implementation still needs care-team confirmation.
Pembrolizumab (Keytruda) with pemetrexed and platinum-based chemotherapy [4]ApprovedNo biomarker requirement stated in fetched NICE TA1125 source; Untreated unresectable advanced malignant pleural mesothelioma in adults. · This is not a positive NICE recommendation. It does not establish routine NHS funding; local decision-making may apply if organisations consider the regimen. Confidence/conflicts: High for no NICE recommendation; conflict with U.S. FDA and EU EMA approvals is jurisdiction/access-specific.
Pembrolizumab (Keytruda) with pemetrexed and platinum-based chemotherapy [4]ApprovedNo biomarker requirement stated in fetched NICE TA1125 source; Untreated unresectable advanced malignant pleural mesothelioma in adults. · This is not a positive NICE recommendation. It does not establish routine NHS funding; local decision-making may apply if organisations consider the regimen. Confidence/conflicts: High for no NICE recommendation; conflict with U.S. FDA and EU EMA approvals is jurisdiction/access-specific.

출처

U.S. Food and Drug Administration (FDA) — regulator approval notice · regulator approval notice
European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
NICE — technology appraisal recommendation · technology appraisal recommendation
NICE — terminated technology appraisal advice · terminated technology appraisal advice

위 내용은 공식 규제·접근 상태일 뿐, 의학적 조언이나 추천이 아니고, 적격성을 판단하지도 않습니다. 어떤 선택지가 적합한지는 환자의 상황과 종양내과 팀에 달려 있습니다. 규제 상태는 바뀔 수 있으니 표시된 출처에서 확인하세요. 임상 세부 내용은 영문이 정본입니다. 최종 확인 2026-06-12.